https://orcid.org/0000-0002-6780-8720
-
Views
-
Cite
Cite
Yaoyu Zhang, Yingying Zhao, Tao Deng, Wenjun Meng, Letter to the Editor From Zhang et al: “Cabozantinib Plus Ipilimumab/Nivolumab in Patients With Previously Treated Advanced Differentiated Thyroid Cancer”, The Journal of Clinical Endocrinology & Metabolism, 2025;, dgaf220, https://doi.org/10.1210/clinem/dgaf220
Close - Share Icon Share
Extract
Dear Editor,
We are desirous to express our appreciation for the insightful publication concerning “Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer” (1). This study by Konda et al showcases a promising therapeutic modality that holds the potential to transform the treatment approach for this patient cohort.
The innovative combination of cabozantinib with the immunotherapy agents ipilimumab and nivolumab constitutes a commendable exploration of the synergistic potential of these medications. Despite the study outcomes not attaining the anticipated high response rates, the attempt to combine these agents in a clinical context is praiseworthy and lays a foundation for future research undertakings.
Nonetheless, we assert that there are areas that could benefit from further deliberation. The patient population in the study was notably homogeneous, with a predominance of oncocytic carcinoma cases. While this concentration offers depth, it might constrict the generalizability of the outcomes. A more diverse representation of differentiated thyroid cancer histologies could furnish a broader understanding of treatment responses among different patient groups.
